These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 6233248)

  • 21. In vitro comparison of norfloxacin with nalidixic acid, cinoxacin and oxolinic acid.
    Vuye A
    Arzneimittelforschung; 1983; 33(12):1623-7. PubMed ID: 6230083
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Belgian multicenter in vitro study of norfloxacin.
    Verbist L
    Acta Clin Belg; 1985; 40(3):167-73. PubMed ID: 3161262
    [No Abstract]   [Full Text] [Related]  

  • 23. Antibacterial activity of norfloxacin.
    Norrby SR; Jonsson M
    Antimicrob Agents Chemother; 1983 Jan; 23(1):15-8. PubMed ID: 6219617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative in vitro activity of norfloxacin and four other chemotherapeutics against urinary gram-negative isolates.
    Esposito S; Galante D; Pennucci C; Barba D; Limauro D; Scioli C
    Chemioterapia; 1984 Jun; 3(3):196-9. PubMed ID: 6241506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro antibacterial activity of norfloxacin and other agents against ocular pathogens.
    Shungu DL; Tutlane VK; Weinberg E; Gadebusch HH
    Chemotherapy; 1985; 31(2):112-8. PubMed ID: 3157551
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Norfloxacin, amoxycillin, cotrimoxazole and nalidixic acid. A summary of 3-day and 7-day therapy studies in the treatment of urinary tract infections.
    Vogel R; Deaney NB; Round EM; VandenBurg MJ; Currie WJ
    J Antimicrob Chemother; 1984 May; 13 Suppl B():113-20. PubMed ID: 6234271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of Urine Matrix and pH on the Potency of Delafloxacin and Ciprofloxacin against Urogenic Escherichia coli and Klebsiella pneumoniae.
    So W; Crandon JL; Nicolau DP
    J Urol; 2015 Aug; 194(2):563-70. PubMed ID: 25637857
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical value of sensitivity determinations in treating urinary tract infections.
    Fair WR; Fair WR
    Urology; 1982 May; 19(5):565-9. PubMed ID: 7043860
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapid selection of organisms with increasing resistance on subinhibitory concentrations of norfloxacin in agar.
    Tenney JH; Maack RW; Chippendale GR
    Antimicrob Agents Chemother; 1983 Jan; 23(1):188-9. PubMed ID: 6219620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of pefloxacin compared to that of quinolones and other antimicrobial agents.
    Neu HC; Chin NX; Labthavikul P; Saha G
    Chemioterapia; 1984 Aug; 3(4):235-41. PubMed ID: 6241847
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The comparative activity of norfloxacin with other antimicrobial agents against Gram-positive and Gram-negative bacteria.
    Corrado ML; Cherubin CE; Shulman M
    J Antimicrob Chemother; 1983 Apr; 11(4):369-76. PubMed ID: 6222023
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The treatment of Pseudomonas aeruginosa urinary tract infections with norfloxacin.
    Leigh DA; Emmanuel FX
    J Antimicrob Chemother; 1984 May; 13 Suppl B():85-8. PubMed ID: 6234280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Norfloxacin in acute urinary tract infections.
    Deaney NB; Vogel R; Vandenburg MJ; Currie WJ
    Practitioner; 1984 Jan; 228(1387):111-7. PubMed ID: 6229726
    [No Abstract]   [Full Text] [Related]  

  • 34. Occurrence of gram negative bacteria in midstream bladder urine and their sensitivity to quinoline derivatives.
    Esposito S; Galante D; Pennucci C; Barba D
    Microbiologica; 1985 Jul; 8(3):269-76. PubMed ID: 3162081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro emergence of Escherichia coli and Pseudomonas aeruginosa strains resistant to norfloxacin and nalidixic acid.
    Piffaretti JC; Demarta A; Leidi-Bulla L; Peduzzi R
    Eur J Clin Microbiol; 1983 Dec; 2(6):600-1. PubMed ID: 6230227
    [No Abstract]   [Full Text] [Related]  

  • 36. [Study of nalidixic acid activity on 3186 strains of Gram negative bacilli. Application to the treatment of urinary infections].
    Chamfeuil R; Curcier H
    Presse Med (1893); 1969 Nov; 77(48):1763-4. PubMed ID: 4903534
    [No Abstract]   [Full Text] [Related]  

  • 37. [Norfloxacin sensitivity of bacterial pathogens of urinary tract infections].
    Modde H
    Schweiz Rundsch Med Prax; 1985 Apr; 74(17):439-42. PubMed ID: 3159064
    [No Abstract]   [Full Text] [Related]  

  • 38. Resistance to quinolones in pathogens causing urinary tract infections.
    Kapoor H; Aggarwal P
    J Commun Dis; 1997 Sep; 29(3):263-7. PubMed ID: 9465532
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frequency of appearance of resistant variants to norfloxacin and nalidixic acid.
    Duckworth GJ; Williams JD
    J Antimicrob Chemother; 1984 May; 13 Suppl B():33-8. PubMed ID: 6234273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors governing the emergence of resistance to nalidixic acid in treatment of urinary tract infection.
    Greenwood D; O'Grady F
    Antimicrob Agents Chemother; 1977 Dec; 12(6):678-81. PubMed ID: 337890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.